Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can standard cancer treatment wake up the immune system? a study investigates.

NCT ID NCT03117946

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Besancon Source: ClinicalTrials.gov ↗

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study looks at how anti-tumor T-cell responses change in people with lung or head-and-neck cancer who are receiving radiochemotherapy. Researchers will collect blood and tumor samples to track immune markers. The goal is to understand whether this standard treatment can boost the body's natural immune attack on cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
concomitant radiochemotherapy (radiation plus chemotherapy)
What this could lead to
If the immune response patterns are better understood, this could point toward ways to boost the body's own defenses during standard cancer treatment.
What could go wrong
This is an observational study measuring immune markers, not testing a new therapy. It may not lead directly to any treatment change.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms lung cancer lung neoplasm non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEAD AND NECK CANCER LUNG CANCER

Contacts and locations

Locations

  • CHU de Besançon

    Besançon, France, 25000, France

  • Centre Georges François LECLERC

    Dijon, 21000, France

  • Hôpital Nord Franche-Comté

    Montbéliard, France

  • Institut Jean Godinot

    Reims, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.